Critique: Makary's exit creates new uncertainty at FDA

Source: axios
Authors: Adriel Bettelheim
URL: https://www.axios.com/2026/05/13/makary-fda-departure-whats-next

What the article reports

Marty Makary has left the FDA after roughly 13 months as commissioner, with Trump citing vague "difficulty" and internal critics pointing to management problems and policy unpredictability. Kyle Diamantas, a Florida lawyer and reported friend of Donald Trump Jr., will serve as acting head. The piece surveys possible successors and the political complications around Senate confirmation of a replacement.

Factual accuracy — Adequate

Most verifiable claims check out at the surface level: Makary is a Johns Hopkins physician, Stephen Hahn served as FDA commissioner under Trump's first term, and Sen. Dick Durbin is an Illinois Democrat. The Trump Truth Social quote and his press-pool remark are attributed directly and plausibly. However, the article states Diamantas was "heading the FDA's food center" without specifying his title — a detail readers would need to evaluate his qualifications. The claim that he is a "reported friend of Donald Trump Jr." rests entirely on "reported," with no sourcing. Similarly, the assertion that Makary was ousted partly over "complaints from health care investors about unpredictable regulatory decisions that rejected some promising drugs" is asserted as fact without a named or documented source. Brett Giroir is described as "briefly acting commissioner," which is accurate but elides his more prominent role as HHS assistant secretary for health — a minor but potentially misleading simplification.

Framing — Uneven

1. "lightning rods for controversy" — The lead frames Makary's entire tenure through the lens of controversy before any evidence is presented. This is authorial characterization, not attributed reporting.
2. "an agency once known for predictability and evidence-based decision-making" — Presented as settled fact in the author's voice; no source or time-frame is given for this characterization. It implies a clear pre-Trump baseline that readers cannot verify from the text.
3. "surprise policy moves, organizational upheaval and political interference" — All three descriptors appear as unattributed authorial claims. "Political interference" in particular is a loaded construction.
4. The sequencing places the critical voices (investors, industry, Durbin's backhanded compliment) prominently, and the one unambiguously positive institutional voice (BIO's Crowley) is used mainly to underscore instability rather than to defend Makary.

Source balance

Ratio: 0 clearly defensive of Makary's record : 3 critical or implicitly critical : 2 neutral-to-positive on narrow points. Unnamed "vaping lobbyists," "independent physicians," and "anti-abortion politicians" are invoked as a bloc but none quoted. Makary himself is not quoted. The "fans, even among some Democrats" are illustrated only by Durbin, whose quote is more an attack on Trump than a defense of Makary.

Omissions

1. Makary's own account. He is not quoted or paraphrased on his departure — a significant gap in a profile of his exit.
2. Specific drug decisions. The claim about "rejected some promising drugs" is cited as a source of investor complaints but no drug name or decision is mentioned, making it impossible to evaluate.
3. DOGE layoff scope. Crowley mentions "sweeping DOGE layoffs" but the article gives no figure or timeframe; readers cannot assess the scale of the staffing crisis that preceded Makary.
4. Historical confirmation timelines. The Senate bandwidth concern is asserted without any data on how long past FDA commissioner confirmations have taken, which would contextualize the urgency.
5. Makary's stated priorities and accomplishments. The article mentions streamlining clinical trials but does not name a single completed regulatory action, leaving readers with no basis to assess what, if anything, he achieved.

What it does well

• The article correctly identifies the political complication of Bill Cassidy's primary weekend as a concrete constraint on Senate action — "whose chairman, Bill Cassidy (R-La), faces a tough primary this weekend against a Trump-endorsed challenger" is a specific, checkable, useful fact.
• The Meekins quote — "Finding someone industry welcomes and MAHA does not despise may be a bit of a challenging channel to navigate" — concisely frames the successor dilemma with a source attached.
• The piece acknowledges Makary had "fans, even among some Democrats in Congress," providing at least a gesture toward the more complex picture before moving on.
• Byline, publication date, and named affiliations for all quoted sources are included — transparency basics are met.

Rating

Overall: 7/10 — A serviceable Washington brief that moves fast and sources key political dynamics well, but relies on unattributed framing and omits the most newsworthy voice — the departing commissioner himself.